Prana touts Phase II results of Huntington drug, shares surgeFeb 18 2014, 08:03 ET | About: Prana Biotechnology Ltd (PRAN) | By: Yigal Grayeff, SA News Editor

• Prana Biotechnology's (PRAN) PBT2 treatment for Huntington disease met its primary endpoints of safety and tolerability in a Phase II study of 109 patients.
• PBT2 also statistically improved executive function among early-stage Huntington's patients who received a 250 mg dose - but not the whole population - was associated with "a favorable signal in functional capacity" and a reduction atrophy of brain tissue.
• However, the drug didn't bring about any significant improvements in other secondary efficacy measures in the study, including motor, functional and behavioral assessments.
• Adam Feuerstein calls these "the most important - and negative - assessment of PB2's efficacy."
• Notwithstanding Feuerstein's skepticism, Prana's share are +14.5%. (PR)